For instance, circulating tumor DNA (ctDNA), particularly BRAF V600E ctDNA, has shown promise as a dynamic biomarker for monitoring treatment response, with a decline in its levels often correlating with positive imaging-based response detection in patients undergoing immunotherapy or targeted treatments, making it a clinically validated tool in practice [49]. Here, BRAF is linked to neoplasm.